Navigation Links
Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
Date:4/7/2008

- Dr. Kantor joins founding management team to direct ITI's Center for

Critical Path Immunology -

SAN FRANCISCO, April 7, 2008 /PRNewswire/ -- The Immune Tolerance Institute Inc., (ITI) today announced that Aaron B. Kantor, Ph.D. has joined the company in the position of Chief Scientific Officer, reporting to Louis A. Matis, M.D., President and Chief Executive Officer. Prior to joining ITI, Dr. Kantor served as Executive Director of Cell and Molecular Biology for Biomarker Discovery Sciences at Pharmaceutical Product Development, Inc. (PPD), a leading global contract research organization (CRO) providing discovery, development and post-approval services and compound partnering programs for pharmaceutical, biotechnology, medical device, academic and government organizations.

"We are very pleased to have Aaron join the founding management team at ITI, as he brings to the company broad-based expertise in applying a range of bioanalytical technologies to the discovery of biological markers for human diseases," said Dr. Matis. "His extensive record of accomplishments in both academic and industry settings will be invaluable to ITI as we build our Center for Critical Path Immunology and leverage the partnering opportunities for our integrated diagnostic platforms."

Dr. Kantor, 49, has more than 20 years of research and development experience. He joined PPD in 2005 when the company acquired the biomarker business of SurroMed, Inc., where he was a founding scientist and director of cell and molecular biology. At PPD, his work centered on the broad effort to discover biological markers for human diseases using bioanalytical methods including cytometry, immunoassays, proteomics, metabolomics and bioinformatics tools. He supervised an interdisciplinary group of scientists and engineers in this effort and led the development and implementation of a laser scanning cytometry platform for clinical studies. His responsibilities
'/>"/>

SOURCE The Immune Tolerance Institute Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
2. Seneca Valley High School Student Receives Science Award From MedImmune
3. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
6. Immune system protein starves staph bacteria
7. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. Peptimmune Announces First Close of Series D Private Financing
10. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
11. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... Applied Biosystems, part of Life Technol...ovative life science research and discovery soluti...generation genomic analysis, the SOLiD™ Syst...the Year for 2008 by The Scientist, a leading scie...ustry. In making the announcement of the first-eve...
(Date:12/3/2008)... Dec. 3 ev3 Inc. (Nasdaq... today announced the appointment of John,L. Miclo... , Mr. Miclot is currently the president an...tely held nationwide provider of various home care...wound care, urology and respiratory,disorders. P...
(Date:12/3/2008).... 3 CeloNova BioSciences, Inc., an...hich it is commercializing the,CATANIA(TM) Corona...tent,system that has not had any stent thrombosis...le for purchase throughout Europe and now some Mid...expansion ongoing. Concurrently,CeloNova notes t...
(Date:12/3/2008)...Dennis will Outline How Technology Can Solve Press... , , KINGSTON, ON, Dec. 3 /PRNewswire/ - Dr...c. (PPI), is one of four leading experts speaking ...ge Conference underway in Poznan , Poland. Dr. Den...lems in the 20th Century and the role it will play...
Breaking Biology Technology: Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5ev3 Inc. Appoints John L. Miclot to Board of Directors 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3Leading Canadian Scientist to speak at UN Climate Change Conference 2
...sperson, one of the first rituals after shaking ha... or her card. In the business world, it is a refle...tualistic. , ,When I visited Japan a few years ag... the business card was so important to the Japanes..."may-shee). I learned to take a card carefully wit...
...the American Cancer Society, one in three people w... lifetime. In an effort to improve patient care an...cal Systems has developed innovative medical imagi...tter detect, diagnose and treat this deadly diseas...m GE include: two digital X-ray technologies desig...
...istics help manufactures manage some of the most c...stics networks in the world. The company will now ... help companies save millions of dollars with impr...der Logistics plans to target customers who choose...o build competitive operations with the industry,s...
...he pay differential between U.S. white collar work...ogrammer ,U.S.: $66,100 ,India: $10,000 , ,IT Mana...S.: $41,000 ,India: $5,000 , Not long ago, jobs le...manufacturing sector, as more and more factories p...an countries to cut costs. Not to mention all the ...
Other Biology Technology:Are You Your Business Card? 2Are You Your Business Card? 3GE Medicals Technologies Aid Battle Against Cancer 2GE Medicals Technologies Aid Battle Against Cancer 3Schneider Logistics Helps Manufacturers Secure Competitive Advantage 2Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 2Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 3
(Date:12/3/2008)...rst tandem mission between ERS-2 and Envisat last ...gain to help improve our understanding of the plan...at, the largest environmental satellite ever built...ments that provide high resolution images of the E...mages of the same site, slight alterations that ma...
(Date:12/3/2008)...e International Society for Stem Cell Research (IS...n of stem cell researchers, released new guideline...ctive stem cell therapies for patients. A Commenta...Clinical Translation of Stem Cells will be publish...em Cell , the official affiliated journal of the I...
(Date:12/3/2008)...ges in voltage that occur across the membrane of a...actor in the process by which these stem cells dif...ts University scientists. , Tufts doctoral stud...l Levin, and Chair of Biomedical Engineering David...paper "Membrane Potential Controls Adipogenic and...
(Date:12/3/2008)...ein and cereal grains produce an excess of acid in... weaken bones, according to a new study accepted f... of Clinical Endocrinology & Metabolism ( JCEM )....t of the diet, with a pill or through a diet rich ...nd strengthens skeletal health. , "Heredity, die...
Breaking Biology News(10 mins):ESA satellites flying in formation 2The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3New 'control knobs' for stem cells identified 2Calcium and vitamin D may not be the only protection against bone loss 2Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC CBS and NBCs Simultaneous Broadca 25992 1Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC CBS and NBCs Simultaneous Broadca 25992 2Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC CBS and NBCs Simultaneous Broadca 25992 3Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 1Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 2Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 3Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 4Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 5Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 6Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 7Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 8Alexzas AZ 004 28Staccato 28R 29 Loxapine 29 Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2937 9Dialysis Patient Citizens Welcomes New Members to Board of Directors 25988 1Dialysis Patient Citizens Welcomes New Members to Board of Directors 25988 2Dialysis Patient Citizens Welcomes New Members to Board of Directors 25988 3Gold Rush 21 The Monks go Gold and Platinum 25983 1
...ts at the University of Cincinnati (UC) have found...Malaysia -- still produce and sell consumer paints...appears in the early online edition of the journal...ber 2006. , The researchers say that this lead-...t, and a worldwide ban is urgently needed to avoid...
...allows scientists peering inside cells to discern ...tein they are studying has been developed and succ...Hughes Medical Institute,s Janelia Farm Research C...ional Institutes of Health and Florida State Unive...lution of conventional optical microscopes, which ...
...s, which prevent genes from producing harmful prot...mise to be more effective than conventional drugs,...s been slow. , Using gold nanoparticles combined w... have demonstrated a new method for developing ant...e agents. The findings will be published May 19 in...
...ations in the p53 tumor-suppressor gene, suggestin...in in defending against cancer. Similarly, roughly... protein occur in its DNA-binding core domain, poi...ivotal to its anti-cancer activity. , Clearly, a ... with DNA could provide important insights into pr...
Other Biology News:Study supports 'urgent' need for worldwide ban on lead-based paint 2Study supports 'urgent' need for worldwide ban on lead-based paint 3New light microscope sharpens scientists' focus 2New light microscope sharpens scientists' focus 3New light microscope sharpens scientists' focus 4New light microscope sharpens scientists' focus 5New light microscope sharpens scientists' focus 6Gold nanoparticles could improve antisense cancer drugs 2Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity 2
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody
Biology Products: